Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.

Medigene AG has provided a pipeline update in its half-year report for the first half of 2024. The company, which develops T cell receptor (TCR)-guided therapies for the treatment of cancer, confirmed for following positive EU and U.S. preliminary regulatory interactions, is on track for filing an IND in Q3 and a CTA in Q4 of 2024 for its lead candidate MDG-1015.

Cidara Therapeutics Inc. announced in its Q2 filing that it received IND clearance for its drug-Fc conjugate (DFC) immunotherapy CBO-421 in July of 2024.

Lantern Pharma Inc. has presented new data on their novel acylfulvene compound LP-184 as a DNA-damaging agent that induces DNA double-strand breaks (DNA DSBs) in cancer cells and may activate immune responses by activation of the cGAS/STING pathway.

Researchers from Mustbio Co. Ltd. and Chung-Ang University have presented the discovery and preclinical characterization of MB-2033, a novel bispecific fusion protein being developed for the treatment of cancer.

Investigators at McMaster University have developed a CAR T cell that targeted roundabout guidance receptor 1 (ROBO1).

Cellular immunotherapy is the Lamine Yamal of cancer therapy. It is easy to forget how young the field is – and that as stunning as it is to watch in action already, it is still reaching its full potential. One aspect of doing so is working in a broader range of tumor types. The field made a giant step toward that goal with last week’s approval of Tecelra (afamitresgene autoleucel, Adaptimmune Therapeutics plc), the first CAR T cell to be approved for treatment of a solid tumor.

Umoja Biopharma Inc. has received clearance from the FDA to begin a first-in-human trial of its CAR T product UB-VV111. The company expects to dose the first patient by the end of 2024.

LTZ Therapeutics Inc. has completed a series A financing of more than $20 million to advance the development of its myeloid engager pipeline to treat cancer and autoimmune diseases. The closing of this round brings LTZ’s total funding to about $50 million.

The dealmaking continues at Boehringer Ingelheim GmbH as it plans to buy Nerio Therapeutics Inc. for $1.3 billion. The German company is bolstering its cancer programs with the Nerio acquisition, which will be added to multibillion-dollar deals cut earlier this year for cancer immunotherapies and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) treatments.